. Author manuscript; available in PMC: 2009 Mar 2.

Published in final edited form as: J Allergy Clin Immunol. 2009 Jan;123(1):146–152.e8. doi: 10.1016/j.jaci.2008.10.047

TABLE E7.

Results of univariate linear regression of the percentage of GSSG in the ELF on clinical features of severe asthma^*

Dependent variable modeled	Regression coefficient (β)	SE	t	P value	95% CI
F_ENO^†
% GSSG	0.012	0.005	2.320	.032	(0.001, 0.022)
Constant	1.810	0.286	6.323	<.001
ICS dose (μg/d)
% GSSG	1.795	2.484	0.723	.477	(−3.332, 6,922)
Constant	671.034	151.425	4.431	<.001
Baseline FEV₁
% GSSG	−0.148	0.092	−1.596	.116	(−0.333, 0.038)
Constant	91.548	5.147	17.787	<.001
FEV₁ reversibility after bronchodilator (%)
% GSSG	0.010	0.096	0.106	.917	(−0.194, 0.214)
Constant	11.000	5.686	1.934	.072

Data are from the combined sample of subjects with severe asthma with and without airway obstruction, excluding adult and pediatric controls.

^†

Data were logarithmically transformed for analysis.